Report cover image

Transverse Myelitis Drug Pipeline Analysis Report 2025

Publisher Expert Market Research
Published May 25, 2025
Length 200 Pages
SKU # EMAR20147076

Description

Transverse myelitis is a rare neurological condition that affects the spinal cord, leading to varying degrees of motor, sensory, and autonomic dysfunction. The disease affects approximately 1.76 per 1,000,000 children aged 19 years and younger globally. Currently, there is a significant unmet clinical need for effective treatments, as existing therapies primarily focus on managing symptoms, such as corticosteroids. However, the growing emphasis on immunomodulatory treatments, stem cell therapies, and targeted molecular therapies is expected to drive the development of novel treatments, offering hope for improved outcomes in the future.

Report Coverage

The Transverse Myelitis Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into transverse myelitis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for transverse myelitis. The transverse myelitis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The transverse myelitis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with transverse myelitis treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to transverse myelitis.

Transverse Myelitis Drug Pipeline Outlook

Transverse myelitis is a rare neurological condition characterized by inflammation of the spinal cord, which can lead to motor, sensory, and autonomic dysfunction. It occurs when the immune system mistakenly attacks the spinal cord, often following infections, autoimmune disorders, or after vaccination. Symptoms include weakness, pain, and sensory issues, with varying severity depending on the affected spinal region.

Transverse myelitis treatment typically involves corticosteroids to reduce inflammation. In some cases, plasma exchange therapy is used to remove harmful antibodies. Additionally, immunosuppressive drugs may help manage underlying conditions, while physical therapy assists in recovery and rehabilitation, aiming to improve mobility and function.

Transverse Myelitis Epidemiology

Studies reveal that the incidence of transverse myelitis in children under 19 years is approximately 1.76 per 1,000,000, with a peak onset of around 9.5 years. In the United States, 1 to 8 new cases are reported per million people annually. Global prevalence ranges from 0.4 to 1.5 per thousand deliveries, with a varying gender distribution, especially in older children.

Transverse Myelitis Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of transverse myelitis drug candidates based on several segmentations including:

By Phase
  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products
By Drug Class
  • Small Molecules
  • Monoclonal Antibodies
  • Others
By Route of Administration
  • Oral
  • Intravenous (IV)
  • Others
Transverse Myelitis – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total transverse myelitis clinical trials.

Transverse Myelitis – Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the transverse myelitis pipeline analysis include small molecules, monoclonal antibodies, and gene therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for transverse myelitis.

Transverse Myelitis Clinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR report for the transverse myelitis report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in transverse myelitis clinical trials:
  • Q Therapeutics, Inc.
  • Alexion Pharmaceuticals, Inc.
  • Guangzhou JOYO Pharma Co., Ltd
  • Amgen
  • Hoffmann-La Roche
  • AstraZeneca
  • Jazz Pharmaceuticals
  • Shanghai Pharmaceuticals Holding Co., Ltd.
Transverse Myelitis Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for transverse myelitis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of transverse myelitis drug candidates.

Biological: Q-Cells

A Phase 1/2a study sponsored by Q Therapeutics, Inc. is evaluating the safety of transplanting human glial restricted progenitor cells (Q-Cells®) into subjects with transverse myelitis (TM). The study aims to assess the safety, tolerability, and early activity of Q-Cells® transplantation in spinal cord lesions.

Drug: Inebilizumab

This drug, sponsored by Hansoh BioMedical R&D company, is currently in a Phase 4 study. The objective of this study is to assess the efficacy and safety of Inebilizumab in Chinese adult patients with neuromyelitis optica spectrum disorders (NMOSD), a condition that includes symptoms like transverse myelitis. The study is expected to be completed by June 2025.

Reasons To Buy This Report

The Transverse Myelitis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for transverse myelitis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within transverse myelitis pipeline insights.

Key Questions Answered in the Transverse Myelitis – Pipeline Insight Report
  • Which companies/institutions are leading the transverse myelitis drug development?
  • What is the efficacy and safety profile of transverse myelitis pipeline drugs?
  • Which company is leading the transverse myelitis pipeline development activities?
  • What is the current transverse myelitis commercial assessment?
  • What are the opportunities and challenges present in the transverse myelitis drug pipeline landscape?
  • What is the efficacy and safety profile of transverse myelitis pipeline drugs?
  • Which company is conducting major trials for transverse myelitis drugs?
  • Which companies/institutions are involved in transverse myelitis collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in transverse myelitis?
Related Reports

Transverse Myelitis Market

Global Clinical Trials Market

Table of Contents

200 Pages
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology & Assumptions
2 Executive Summary
3 Overview of Transverse Myelitis
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Diagnosis
3.5 Treatment
4 Patient Profile: Transverse Myelitis
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Transverse Myelitis: Epidemiology Snapshot
5.1 Transverse Myelitis Incidence by Key Markets
5.2 Transverse Myelitis – Patients Seeking Treatment in Key Markets
6 Transverse Myelitis: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Transverse Myelitis: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Transverse Myelitis, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of Transverse Myelitis Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Transverse Myelitis Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Drug: Inebilizumab
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Other Drugs
11 Transverse Myelitis Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Drugs: JYP0061, Intravenous Glucocorticoids, Oral Glucocorticoids
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Other Drugs
12 Transverse Myelitis Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Drug 1
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Other Drugs
13 Transverse Myelitis Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Other Drugs
14 Transverse Myelitis, Key Drug Pipeline Companies
14.1 Q Therapeutics, Inc.
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 Alexion Pharmaceuticals, Inc.
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Guangzhou JOYO Pharma Co., Ltd
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Amgen
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Jazz Pharmaceuticals
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 Hoffmann-La Roche
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
14.7 AstraZeneca
14.7.1 Company Snapshot
14.7.2 Pipeline Product Portfolio
14.7.3 Financial Analysis
14.7.4 Recent News and Developments
14.8 Shanghai Pharmaceuticals Holding Co., Ltd
14.8.1 Company Snapshot
14.8.2 Pipeline Product Portfolio
14.8.3 Financial Analysis
14.8.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region
16 Terminated or Suspended Pipeline Products

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us